Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study — Hohhot City, Inner Mongolia Autonomous Region, China, 2022

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron sub-variants in vitro studies. WHAT IS ADDED BY THIS REPORT? This study demonstrated the safety and effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Shujie, Jin, Canrui, Li, Jianping, Cao, Yunlong, Kan, Biao, Xue, Feng, Xie, Xiaoliang Sunney, Fang, Liang, Zeng, Gang, Zhang, Shuo, Hu, Yaling, Dong, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023
Materias:
Preplanned Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061814/
https://www.ncbi.nlm.nih.gov/pubmed/37006441
http://dx.doi.org/10.46234/ccdcw2023.040
Descripción
Sumario:WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron sub-variants in vitro studies. WHAT IS ADDED BY THIS REPORT? This study demonstrated the safety and effectiveness of SA58 Nasal Spray against coronavirus disease 2019 (COVID-19) infection in medical personnel for the first time. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? This study provides an effective approach for the public to reduce their risk of COVID-19 infection. The findings of this research have the potential to significantly reduce the risk of infection and limit human-to-human transmission in the event of a COVID-19 outbreak.

Ejemplares similares